Piqray 150 mg Alternative – Alpesib (Alpelisib) 150 mg Tablet | Everest Pharmaceuticals
Alpesib 150 mg (Alpelisib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Piqray (Novartis). It belongs to the PI3K-alpha inhibitor class and is used in selected PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer regimens.
Active ingredient: Alpelisib
Strength: 150 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Product Overview
Alpesib 150 mg Tablet by Everest Pharmaceuticals Ltd., Bangladesh contains Alpelisib. It is listed here as a same-ingredient branded option for people researching Piqray, a reference brand associated with Novartis. Alpesib and Piqray must not be assumed to have identical formulations, approved indications or demonstrated bioequivalence. This page refers only to the 150 mg strength.
Alpesib vs. Piqray – Originator / Reference Brand Comparison
Piqray is a widely recognized reference brand for Alpelisib associated with Novartis. Alpesib is the Everest Pharmaceuticals product listed in this catalogue. The comparison identifies a shared active ingredient; the exact strength, dosage form, excipients, product registration and interchangeability must be checked for each marketed presentation. Reference-brand naming does not mean Alpesib is manufactured by Novartis, approved by the same regulator or automatically substitutable. In particular, different formulations and release forms must not be treated as interchangeable.
Composition and Active Ingredient
Active ingredient: Alpelisib
Strength: 150 mg
Dosage form: Tablet
Pharmacological class: PI3K-alpha inhibitor
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh.
The complete inactive ingredient list and product-specific pack presentation require confirmation from the manufacturer’s current label.
Therapeutic Uses and Indications
Alpelisib is used in selected PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer regimens. The applicable indication depends on the specific formulation, country authorization, diagnosis, biomarker results where relevant, and previous treatment. The information describes the generic medicine’s recognized therapeutic context; it does not independently verify every indication for the Everest product in every country. Only a specialist can establish whether the medicine is suitable for an individual patient.
Mechanism of Action – How Alpelisib Works
Alpelisib is a PI3K-alpha inhibitor. In general, it blocks PI3K-alpha signaling that can drive tumor growth. The medicine’s effects depend on disease biology, dosing, combinations with other treatments and patient factors. Mechanism of action alone does not establish effectiveness for an individual patient or a particular unapproved use.
Dosage and Administration
The product contains 150 mg per tablet; this is not a recommended daily dose. A prescriber determines the appropriate regimen based on the indication, laboratory results, organ function, interactions and adverse effects. Follow the approved product leaflet for food instructions, missed doses, handling and treatment duration. Never adjust the dose or replace another brand or strength without medical authorization.
Contraindications
Do not use this medicine if a clinician has identified a contraindication, including known hypersensitivity to its ingredients where applicable. Additional restrictions vary by active ingredient, formulation, disease and pregnancy status. The complete contraindication list must be checked in the locally approved prescribing information before treatment.
Warnings and Precautions
Important precautions for Alpelisib include: high blood glucose, severe rash, diarrhea and hypersensitivity. Patients should discuss liver or kidney disease, cardiac conditions, blood count abnormalities, pregnancy plans and concurrent treatments with the prescribing team. Depending on the medicine, regular laboratory testing, electrocardiograms, blood pressure checks or other monitoring may be necessary. The product’s official safety labeling governs specific requirements.
Possible Side Effects
The adverse-effect profile of Alpelisib varies by indication and combination regimen. Relevant potential adverse effects and serious risks include high blood glucose, severe rash, diarrhea and hypersensitivity. Other symptoms can occur, and not everyone experiences the same effects. Seek prompt medical attention for severe, unexpected or rapidly worsening symptoms, and consult the current patient leaflet for urgent warning signs.
Drug Interactions
Prescription medicines, over-the-counter products, herbal supplements and certain foods can change the effectiveness or safety of Alpelisib. The interaction profile is ingredient-specific; a clinician or pharmacist should review all concurrent treatments before therapy. Never add, stop or change another medicine based solely on this online description.
Pregnancy, Fertility and Breastfeeding
Many anticancer and hematology medicines can harm a developing fetus or require specific contraception and breastfeeding precautions. People who are pregnant, planning pregnancy or breastfeeding should not start Alpelisib without specialist advice. Exact pregnancy testing, contraception duration and breastfeeding restrictions must be checked in the official labeling for this medicine.
Storage and Handling
Store the medicine according to the instructions on the actual Everest Pharmaceuticals pack, protecting it from unsuitable heat, humidity and light as directed. Keep it in its original packaging, away from children, and do not use expired or damaged packs. Some anticancer medicines require additional safe-handling precautions.
Why Is Alpesib Listed as an Alternative to Piqray?
This listing helps customers identify an Everest Pharmaceuticals product containing Alpelisib while researching Piqray. The term alternative refers to the active ingredient and therapeutic context, not proof of identical regulatory status, bioequivalence or permission to substitute. Confirm the exact formulation and strength with the treating clinician and check the destination country’s medicine registration and import rules.
Manufacturer Information
Listed brand: Alpesib
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Reference brand: Piqray
Reference company: Novartis
Generic ingredient: Alpelisib
Strength: 150 mg
Dosage form: Tablet
Therapeutic class: PI3K-alpha inhibitor
Frequently Asked Questions
What is Alpesib 150 mg?
It is an Everest Pharmaceuticals tablet containing Alpelisib 150 mg.
Is Alpesib the same as Piqray?
They are presented as brands associated with Alpelisib, but brand, formulation, approvals and product-specific evidence can differ. No automatic equivalence is established.
What is Alpelisib used for?
Alpelisib is used in selected PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer regimens, subject to the applicable label and clinical assessment.
How does Alpelisib work?
It blocks PI3K-alpha signaling that can drive tumor growth.
Can I switch strengths or brands myself?
No. A licensed prescriber or pharmacist must assess any substitution.
Is a prescription needed?
Yes. This medicine requires appropriate prescription and specialist oversight under applicable laws.
Important Medical Disclaimer
This page provides educational pharmaceutical identification information, not personal medical advice. Prescribing, dispensing and any substitution must be based on current authorized labeling, patient assessment and applicable laws. Product-specific registration and equivalence have not been independently established by this catalogue.
| Generic Name | Alpelisib |
|---|---|
| Strength | 150 mg |
| Manufacturer | Everest Pharmaceuticals Ltd. |
| Pack Size | 28 tablets |
Related products
Casodex 50 mg Alternative – Calupros (Bicalutamide) 50 mg Tablet | Everest Pharmaceuticals
Calupros 50 mg (Bicalutamide) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Casodex (AstraZeneca). It belongs to the nonsteroidal antiandrogen class and is used in selected prostate cancer hormonal treatment regimens.
Active ingredient: Bicalutamide
Strength: 50 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Erleada 60 mg Alternative – Prostaxen (Apalutamide) 60 mg Tablet | Everest Pharmaceuticals
Prostaxen 60 mg (Apalutamide) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Erleada (Janssen). It belongs to the androgen receptor inhibitor class and is used in selected castration-resistant or castration-sensitive prostate cancer settings.
Active ingredient: Apalutamide
Strength: 60 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Gleevec / Glivec 100 mg Alternative – Imaxen (Imatinib) 100 mg Tablet | Everest Pharmaceuticals
Imaxen 100 mg (Imatinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Gleevec / Glivec (Novartis). It belongs to the BCR-ABL/KIT/PDGFR kinase inhibitor class and is used in selected chronic myeloid leukemia and gastrointestinal stromal tumor settings.
Active ingredient: Imatinib
Strength: 100 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Ibrance 125 mg Alternative – Palker (Palbociclib) 125 mg Capsule | Beacon Pharmaceuticals
Kisqali 200 mg Alternative – Ribolib (Ribociclib) 200 mg Tablet | Beacon Pharmaceuticals
Lumakras / Lumykras 120 mg Alternative – Sotoxen (Sotorasib) 120 mg Tablet | Everest Pharmaceuticals
Sotoxen 120 mg (Sotorasib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Lumakras / Lumykras (Amgen). It belongs to the KRAS G12C inhibitor class and is used in selected KRAS G12C-mutated non-small cell lung cancer.
Active ingredient: Sotorasib
Strength: 120 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Tagrisso 80 mg Alternative – Osimert (Osimertinib) 80 mg Tablet | Everest Pharmaceuticals
Osimert 80 mg (Osimertinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Tagrisso (AstraZeneca). It belongs to the EGFR tyrosine kinase inhibitor class and is used in selected EGFR-mutated non-small cell lung cancer.
Active ingredient: Osimertinib
Strength: 80 mg
Form: Tablet
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.
Xalkori 250 mg Alternative – Alkixen (Crizotinib) 250 mg Capsule | Everest Pharmaceuticals
Alkixen 250 mg (Crizotinib) by Everest Pharmaceuticals Ltd. is listed as an alternative-brand option for customers researching Xalkori (Pfizer). It belongs to the ALK/ROS1 kinase inhibitor class and is used in selected ALK-positive or ROS1-positive non-small cell lung cancer.
Active ingredient: Crizotinib
Strength: 250 mg
Form: Capsule
Manufacturer: Everest Pharmaceuticals Ltd., Bangladesh
Prescription required. Shared active ingredients do not establish bioequivalence or automatic interchangeability.

Reviews
There are no reviews yet.